PMID- 24641566
OWN - NLM
STAT- MEDLINE
DCOM- 20141110
LR  - 20181202
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 4
DP  - 2014 Apr
TI  - Axitinib safety in metastatic renal cell carcinoma: suggestions for daily 
      clinical practice based on case studies.
PG  - 497-510
LID - 10.1517/14740338.2014.888413 [doi]
AB  - INTRODUCTION: Axitinib , a highly selective inhibitor of vascular endothelial 
      growth factor receptors taken orally, is approved for second-line treatment of 
      advanced renal cell carcinoma (RCC) after failure of prior treatment with 
      sunitinib or a cytokine. We review data for axitinib and discuss strategies to 
      manage or prevent adverse events (AEs) and maximize clinical benefit. AREAS 
      COVERED: A literature search identified key advanced RCC trials of axitinib and 
      other targeted therapies. Each author also contributed a clinical case study to 
      illustrate management approaches in patients who received axitinib following 
      sunitinib in the AXIS Phase III trial. Axitinib has demonstrated a predictable 
      and manageable AE profile in clinical trials; most commonly reported 
      treatment-related events are diarrhea, hypertension, fatigue, nausea, vomiting 
      and dysphonia. Case studies demonstrate that successful management requires 
      patient awareness of potential AEs, regular monitoring and dose modification for 
      specific AEs. EXPERT OPINION: Improvement in progression-free survival with 
      axitinib versus sorafenib in a Phase III trial supports preferred selection of 
      axitinib in the second-line setting. The safety profile of axitinib versus 
      mammalian target of rapamycin inhibitors and sorafenib also provides the 
      opportunity to personalize treatment in advanced RCC based on the likelihood for 
      specific AEs to occur and on prior toxicities in the first-line setting.
FAU - Bracarda, Sergio
AU  - Bracarda S
AD  - Ospedale San Donato, Medical Oncology , Arezzo, 52100 , Italy 
      sergio.bracarda@usl8.toscana.it.
FAU - Castellano, Daniel
AU  - Castellano D
FAU - Procopio, Giuseppe
AU  - Procopio G
FAU - Sepulveda, Juan M
AU  - Sepulveda JM
FAU - Sisani, Michele
AU  - Sisani M
FAU - Verzoni, Elena
AU  - Verzoni E
FAU - Schmidinger, Manuela
AU  - Schmidinger M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Imidazoles)
RN  - 0 (Indazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - C9LVQ0YUXG (Axitinib)
SB  - IM
MH  - Axitinib
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Clinical Trials, Phase III as Topic
MH  - Disease-Free Survival
MH  - Humans
MH  - Imidazoles/*adverse effects/*therapeutic use
MH  - Indazoles/*adverse effects/*therapeutic use
MH  - Kidney Neoplasms/*drug therapy
MH  - Protein Kinase Inhibitors/adverse effects/therapeutic use
EDAT- 2014/03/20 06:00
MHDA- 2014/11/11 06:00
CRDT- 2014/03/20 06:00
PHST- 2014/03/20 06:00 [entrez]
PHST- 2014/03/20 06:00 [pubmed]
PHST- 2014/11/11 06:00 [medline]
AID - 10.1517/14740338.2014.888413 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Apr;13(4):497-510. doi: 10.1517/14740338.2014.888413.